Figure 6

Associations of RFC2 expression with disease-free interval (DFI) and progression-free interval (PFI) across cancers in TCGA cohort. (A) Forest plot showing the correlation of RFC2 expression with DFI in 33 types of cancer. (B–D) Kaplan–Meier survival analyses displaying the relationships of RFC2 expression with DFI in different cancer types, including diffuse lower-grade gliomas (LGG) (B), liver hepatocellular carcinoma (LIHC) (C), and prostate Cancer (PRAD) (D). (E) Forest plot showing the correlation of RFC2 expression with PFI in 33 types of cancer. (F–O) Kaplan–Meier survival analyses displaying the relationships of RFC2 expression with PFI in different cancer types, including LGG (F), adrenocortical carcinoma (ACC) (G), kidney chromophobe (KICH) (H), kidney renal clear cell carcinoma (KIRC) (I), LIHC (J), lung adenocarcinoma (LUAD) (K), mesothelioma (MESO) (L), pancreatic cancer (PAAD) (M), prostate adenocarcinoma (PRAD) (N), and ocular melanomas (UVM) (O).